Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Interest & Investment Income (2022 - 2025)

Foghorn Therapeutics has reported Interest & Investment Income over the past 4 years, most recently at $1.7 million for Q4 2025.

  • Quarterly results put Interest & Investment Income at $1.7 million for Q4 2025, down 44.7% from a year ago — trailing twelve months through Dec 2025 was $8.7 million (down 26.51% YoY), and the annual figure for FY2025 was $8.7 million, down 26.51%.
  • Interest & Investment Income for Q4 2025 was $1.7 million at Foghorn Therapeutics, down from $2.0 million in the prior quarter.
  • Over the last five years, Interest & Investment Income for FHTX hit a ceiling of $3.5 million in Q3 2024 and a floor of $235000.0 in Q1 2022.
  • Median Interest & Investment Income over the past 4 years was $2.5 million (2023), compared with a mean of $2.3 million.
  • Biggest five-year swings in Interest & Investment Income: skyrocketed 1035.74% in 2023 and later plummeted 44.7% in 2025.
  • Foghorn Therapeutics' Interest & Investment Income stood at $2.4 million in 2022, then grew by 11.95% to $2.7 million in 2023, then rose by 16.39% to $3.1 million in 2024, then plummeted by 44.7% to $1.7 million in 2025.
  • The last three reported values for Interest & Investment Income were $1.7 million (Q4 2025), $2.0 million (Q3 2025), and $2.3 million (Q2 2025) per Business Quant data.